---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-22-001569"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:40:58.175034+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mirum Q3 LIVMARLI sales $18.8M; raises FY2022 guidance to $70M

## Summary
- Net product sales LIVMARLI $18.8M in Q3; YTD $47.2M; raised FY2022 guidance to $70M.
- Reported Q3 net loss $35.7M ($1.02/share) vs $47.1M loss ($1.55/share) in Q3 2021.
- Positive CHMP opinion for LIVMARLI in Alagille syndrome; EU decision expected Q4 2022.
- Positive Phase 3 MARCH data in PFIC; completed public offering netting $86.1M.
- Cash $285.3M at Sept 30; upcoming data: EMBARK Ph2b H2 2023, OHANA Ph2b H1 2023.

## SEC filing metadata
- accession: 0001157523-22-001569
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000115752322001569/0001157523-22-001569-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000115752322001569/a52964746.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-22-001569
- JSON: https://secwatch.observer/filing/0001157523-22-001569.json
- Plain text: https://secwatch.observer/filing/0001157523-22-001569.txt

## Key facts
- Earnings Releases
  Mirum Pharmaceuticals, Inc. reported the quarter ended September 30, 2022 results: revenue $18.8 million, net income net loss of $35.7 million, EPS $1.02 basic and diluted net loss per share.
  - Period: the quarter ended September 30, 2022
  - Revenue: $18.8 million
  - Net income: net loss of $35.7 million
  - EPS: $1.02 basic and diluted net loss per share
  - Result: reported results
  source text: 99.1 Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update - Net product sales for LIVMARLI ® (maralixibat) oral solution totaled $18.8 million in the third quarter of 2022 and $47.2 million year-to-date - Mirum raises 2022 full year net product sales guidance estimate for LIVMARLI to $70 million - Conference call to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000115752322001569/0001157523-22-001569-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.